FDA Reprint Policy Expands To Clinical Practice Guidelines, Medical Reference Texts
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA has revised, but not loosened, its 2009 final guidance on good reprint practices for distribution of journal articles on unapproved uses of approved drugs and devices.
You may also be interested in...
If The ‘SIUU’ Fits: The New Vocabulary Of US FDA ‘Off-Label’ Policy
An updated US FDA policy governing dissemination of ‘off-label’ journal reprints and other scientific communications suggests the agency feels on firmer legal ground to reaffirm some guardrails. It also expands the regulatory vocabulary to include ‘scientific information on unapproved uses,’ or SIUU.
Off-Label Guidance Creates ‘Safe Harbor’ For Dissemination of Certain Info To HCPs
The FDA's revised draft guidance on scientific communications to health care providers about unapproved uses of products describes the studies that are likely to be scientifically sound and clinically relevant. The agency also gives recommendations on presenting off-label information on web pages and in exhibit halls.
Rx Drug Promotion Studies Target Biosimilar Disclosures, Unapproved Uses, Multiple Indications
US FDA proposes studies to look at the impact of disclosure of a product’s secondary claims and biosimilar designation; disclosure about unapproved uses; and the impact of citing a drug’s multiple indications in TV ads.